Thirty years of hemovigilance – Achievements and future perspectives

Vuk, Tomislav; Politis, C.; Laspina, Stefan; Lozano, Miquel; Haddad, Antoine; Angelis, Vincenzo De; Garraud, Olivier

doi:10.1016/j.tracli.2022.09.070

Cited by 8 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Today, more than 100 million RBC units are transfused each year worldwide [2, 3] and the use of big data in these transfusion data has the potential to further enhance the safety, efficiency, and effectiveness of transfusion medicine [4]. One way to conceptualize the application of big data to transfusion medicine is to combine various types of health data, including electronic health records [5, 6], electronic medical records [7], personal health records [8], laboratory information systems [9], medical practice management [10] software, and hemovigilance data [11]. This combination creates a large database that healthcare professionals can use to identify patterns and trends, leading to improved practices in blood product usage, inventory management, and more, ultimately, improving patient outcomes [4, 12].…”

Section: Introductionmentioning

confidence: 99%

Big Data in Transfusion Medicine and Artificial Intelligence Analysis for Red Blood Cell Quality Control

Lopes¹,

Recktenwald²,

Simionato³

et al. 2023

Transfus Med Hemother

View full text Add to dashboard Cite

Background: “Artificial intelligence” and “big data” increasingly take the step from just being interesting concepts to being relevant or even part of our lives. This general statement holds also true for transfusion medicine. Besides all advancements in transfusion medicine, there is not yet an established red blood cell quality measure, which is generally applied. Summary: We highlight the usefulness of big data in transfusion medicine. Furthermore, we emphasize in the example of quality control of red blood cell units the application of artificial intelligence. Key Messages: A variety of concepts making use of big data and artificial intelligence are readily available but still await to be implemented into any clinical routine. For the quality control of red blood cell units, clinical validation is still required.

show abstract

Section: Introductionmentioning

confidence: 99%

Big Data in Transfusion Medicine and Artificial Intelligence Analysis for Red Blood Cell Quality Control

Lopes¹,

Recktenwald²,

Simionato³

et al. 2023

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…Platelet (PLT) transfusions have a higher risk of bacterial contamination than other blood components due to room temperature storage. Infectious disease contamination in the PLT supply has been reduced from improved methods of component collection, viral/parasitic donor screening, and bacterial testing 1,2 . Despite these measures, residual risk of bacterial infection prompted the United States Food and Drug Administration (FDA) in 2020 to institute additional guidance for PLT products including pathogen reduction technology (PRT), a proactive approach to reduce the risk of transfusion‐transmitted diseases in the PLT supply.…”

Section: Introductionmentioning

confidence: 99%

Results of clinical effectiveness of conventional versus Mirasol‐treated Apheresis Platelets in Patients with Hypoproliferative Thrombocytopenia (MiPLATE) trial

Koepsell,

Stolla,

Sedjo

et al. 2024

Transfusion

View full text Add to dashboard Cite

BackgroundThe Mirasol® Pathogen Reduction Technology System was developed to reduce transfusion‐transmitted diseases in platelet (PLT) products.Study Design and MethodsMiPLATE trial was a prospective, multicenter, controlled, randomized, non‐inferiority (NI) study of the clinical effectiveness of conventional versus Mirasol‐treated Apheresis PLTs in participants with hypoproliferative thrombocytopenia. The novel primary endpoint was days of ≥Grade 2 bleeding with an NI margin of 1.6.ResultsAfter 330 participants were randomized, a planned interim analysis of 297 participants (145 MIRASOL, 152 CONTROL) receiving ≥1 study transfusion found a 2.79‐relative rate (RR) in the MIRASOL compared to the CONTROL in number of days with ≥Grade 2 bleeding (95% confidence interval [CI] 1.67–4.67). The proportion of subjects with ≥Grade 2 bleeding was 40.0% (n = 58) in MIRASOL and 30.3% (n = 46) in CONTROL (RR = 1.32, 95% CI 0.97–1.81, p = .08). Corrected count increments were lower (p < .01) and the number of PLT transfusion episodes per participant was higher (RR = 1.22, 95% CI 1.05–1.41) in MIRASOL. There was no difference in the days of PLT support (hazard ratio = 0.86, 95% CI 0.68–1.08) or total number of red blood cell transfusions (RR = 1.12, 95% CI 0.91–1.37) between MIRASOL versus CONTROL. Transfusion emergent adverse events were reported in 119 MIRASOL participants (84.4%) compared to 133 (82.6%) participants in CONTROL (p = NS).DiscussionThis study did not support that MIRASOL was non‐inferior compared to conventional platelets using the novel endpoint number of days with ≥Grade 2 bleeding in MIRASOL when compared to CONTROL.

show abstract

“…The transfusion of blood products is lifesaving in the presence of severe anemia or bleeding, and it is essential to support aplasia during bone marrow reconstitution after hematopoietic stem cell transplantation (HSCT) [ 1 , 2 ]. However, blood resources are limited and costly and are not risk-free, as some transfusion-transmitted infections and/or adverse transfusion reactions (acute and late) may occur, despite the high safety of blood products [ 3 , 4 , 5 ]. In order to optimize the transfusion strategy, during the last decades several studies have been conducted in many different medical fields (i.e., surgery) introducing the concept of patient blood management (PBM) [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Patient Blood Management after Hematopoietic Stem Cell Transplantation in a Pediatric Setting: Starting Low and Going Lower

et al. 2023

View full text Add to dashboard Cite

Despite the substantial transfusion requirements, there are few studies on the optimal transfusion strategy in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT). Our study aimed to retrospectively analyze red blood cell (RBC) and platelet (PLT) transfusion practices during the first 100 days after HSCT at the pediatric hematology/oncology unit of our hospital between 2016 and 2019, due to a more restrictive approach adopted after 2016. We also evaluated the impact on patient outcomes. A total of 146 consecutive HSCT patients were analyzed. In patients without hemorrhagic complications, the Hb threshold for RBC transfusions decreased significantly from 2016 to 2017 (from 7.8 g/dL to 7.3 g/dL; p = 0.010), whereas it remained the same in 2017, 2018, and 2019 (7.3, 7.2, and 7.2 g/dL, respectively). Similarly, the PLT threshold decreased significantly from 2016 to 2017 (from 18,000 to 16,000/μL; p = 0.026) and further decreased in 2019 (15,000/μL). In patients without severe hemorrhagic complications, the number of RBC and PLT transfusions remained very low over time. No increase in 100-day and 180-day non-relapse mortality or adverse events was observed during the study period. No patient died due to hemorrhagic complications. Our preliminary observations support robust studies enrolling HSCT patients in patient blood management programs.

show abstract

Thirty years of hemovigilance – Achievements and future perspectives

Cited by 8 publications

References 46 publications

Big Data in Transfusion Medicine and Artificial Intelligence Analysis for Red Blood Cell Quality Control

Big Data in Transfusion Medicine and Artificial Intelligence Analysis for Red Blood Cell Quality Control

Results of clinical effectiveness of conventional versus Mirasol‐treated Apheresis Platelets in Patients with Hypoproliferative Thrombocytopenia (MiPLATE) trial

Patient Blood Management after Hematopoietic Stem Cell Transplantation in a Pediatric Setting: Starting Low and Going Lower

Contact Info

Product

Resources

About